These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12923828)

  • 41. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
    Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
    Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine.
    Ansseau M; von Frenckell R; Gérard MA; Mertens C; De Wilde J; Botte L; Devoitille JM; Evrard JL; De Nayer A; Darimont P
    Eur Neuropsychopharmacol; 1991 May; 1(2):113-21. PubMed ID: 1821700
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of intrathecal administration of newer antidepressants on mechanical allodynia in rat models of neuropathic pain.
    Ikeda T; Ishida Y; Naono R; Takeda R; Abe H; Nakamura T; Nishimori T
    Neurosci Res; 2009 Jan; 63(1):42-6. PubMed ID: 18992286
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Possibility of a pharmacogenetic approach for prediction and personalized medication in major depressive disorder treatment].
    Kato M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):83-92. PubMed ID: 20491282
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan.
    Chang TT; Lêng CH; Wu JY; Lee SY; Wang YS; Chen YC; Lu RB
    Chin J Physiol; 2008 Dec; 51(6):387-93. PubMed ID: 19280883
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patient satisfaction with antidepressants: an Internet-based study.
    Shigemura J; Sato Y; Yoshino A; Nomura S
    J Affect Disord; 2008 Apr; 107(1-3):155-60. PubMed ID: 17881062
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients.
    Kiev A; Feiger A
    J Clin Psychiatry; 1997 Apr; 58(4):146-52. PubMed ID: 9164424
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differences in clinical effect and tolerance between fluvoxamine and paroxetine: a switching study in patients with depression.
    Suzuki Y; Tsuneyama N; Fukui N; Sugai T; Watanabe J; Ono S; Someya T
    Hum Psychopharmacol; 2010 Nov; 25(7-8):525-9. PubMed ID: 20860067
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.
    Papakostas GI; Fava M
    Eur Neuropsychopharmacol; 2007 Jan; 17(1):32-6. PubMed ID: 16762534
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Review of pharmacological efficacies and side effects of antidepressants].
    Ikenouchi-Sugita A; Yoshimura R; Nakamura J
    Nihon Rinsho; 2007 Sep; 65(9):1633-7. PubMed ID: 17876986
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Response rate obtained using milnacipran depending on the severity of depression in the treatment of major depressive patients.
    Sugawara Y; Higuchi H; Yoshida K; Takahashi H; Kamata M; Naito S; Sato K; Shimizu T
    Clin Neuropharmacol; 2006; 29(1):6-9. PubMed ID: 16518126
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Can Minnesota Multiphasic Personality Inventory-2 predict response to selective serotonin reuptake inhibitors in depressed outpatients?
    Kertzman S; Vainder M; Reznik I; Gotzlav Y; Weizman A; Kotler M; Iancu I
    Int Clin Psychopharmacol; 2012 May; 27(3):134-41. PubMed ID: 22415223
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression.
    Katz MM; Tekell JL; Bowden CL; Brannan S; Houston JP; Berman N; Frazer A
    Neuropsychopharmacology; 2004 Mar; 29(3):566-79. PubMed ID: 14627997
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees.
    Franchini L; Serretti A; Gasperini M; Smeraldi E
    J Psychiatr Res; 1998; 32(5):255-9. PubMed ID: 9789202
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Augmentation of milnacipran by risperidone in treatment for major depression.
    Tani K; Takei N; Kawai M; Suzuki K; Sekine Y; Toyoda T; Minabe Y; Mori N
    Int J Neuropsychopharmacol; 2004 Mar; 7(1):55-8. PubMed ID: 14731310
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Venlafaxine, paroxetine and milnacipran for major depressive disorder: a pragmatic 24-week study.
    Chuang HY; Chang YH; Cheng LY; Wang YS; Chen SL; Chen SH; Chu CH; Lee IH; Chen PS; Yeh TL; Yang YK; Lu RB
    Chin J Physiol; 2014 Oct; 57(5):265-70. PubMed ID: 25241986
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.
    Yoshimura R; Mitoma M; Sugita A; Hori H; Okamoto T; Umene W; Ueda N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1034-7. PubMed ID: 17459550
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
    Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T
    Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Psychiatric comorbidities and use of milnacipran in patients with chronic dizziness.
    Horii A; Imai T; Kitahara T; Uno A; Morita Y; Takahashi K; Inohara H
    J Vestib Res; 2016 Jul; 26(3):335-40. PubMed ID: 27392838
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Possible predictors of response to fluvoxamine for depression.
    Morishita S; Arita S
    Hum Psychopharmacol; 2003 Apr; 18(3):197-200. PubMed ID: 12672171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.